FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283456543> ?p ?o ?g. }

• W4283456543 endingPage "101366" @default.
• W4283456543 startingPage "101366" @default.
• W4283456543 abstract "Glucagon-like peptide 1(GLP-1) receptor agonists are used in patients with type 2 diabetes as hypoglycemic drugs; a growing body of evidence has clarified their renoprotective benefits. We performed a meta-analysis to summarize the most recent evidence on the renal benefits of GLP-1 receptor agonists from clinical trials of patients with type 2 diabetes. This meta-analysis used a fixed-effects model to estimate the risk ratio (RR) with 95% confidence intervals (CIs) to investigate the effect of GLP-1 receptor agonists on the renal protection. The outcomes were a composite renal outcome, estimated glomerular filtration rate (eGFR) decrease, new macroalbuminuria, doubling of serum creatinine, end-stage renal disease (ESRD) and renal death. We also checked the composite renal outcome of the patient subgroups based on the structural source of human GLP-1 or exendin-4. Among the 12 articles screened, seven studies involving 48101 patients met pre-specified criteria and were included. In general, the use of GLP-1 receptor agonists reduced the risk of the composite renal outcome by 17% (RR 0·83 [95% CI 0·79–0·88]; P < 0·00001), with no significant interaction in subgroups analysis (P = 0.66); the risk of new-onset of persistent macroalbuminuria was reduced by 25% (RR 0·75 [95%CI 0·69–0·81]; P < 0·00001) compared to placebo. However, GLP-1 receptor agonists had no significant effect on eGFR decrease (RR 0·92 [95% CI 0·83–1.01]; P = 0·09), doubling of serum creatinine (RR 0·97 [95% CI 0·78–1.21]; P = 0·79), or end-stage renal disease (RR 0·81 [95% CI 0·62–1.06]; P = 0·12) compared to placebo or insulin glargine (AWARD-7) in patients with type 2 diabetes. GLP-1 receptor agonists, regardless of their structural homology, have significant benefits in reducing the risk of the composite renal outcome, especially in new macroalbuminuria compared with placebo or insulin glargine in patients with type 2 diabetes." @default.
• W4283456543 created "2022-06-26" @default.
• W4283456543 creator A5009232538 @default.
• W4283456543 creator A5019157994 @default.
• W4283456543 creator A5021900458 @default.
• W4283456543 creator A5054522724 @default.
• W4283456543 creator A5073994421 @default.
• W4283456543 date "2022-09-01" @default.
• W4283456543 modified "2023-10-16" @default.
• W4283456543 title "Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis" @default.
• W4283456543 cites W1969068062 @default.
• W4283456543 cites W1988049600 @default.
• W4283456543 cites W1990025047 @default.
• W4283456543 cites W2027570649 @default.
• W4283456543 cites W2068776590 @default.
• W4283456543 cites W2090360729 @default.
• W4283456543 cites W2114598208 @default.
• W4283456543 cites W2126930838 @default.
• W4283456543 cites W2141082354 @default.
• W4283456543 cites W2147222003 @default.
• W4283456543 cites W2161569030 @default.
• W4283456543 cites W2282578582 @default.
• W4283456543 cites W2475233216 @default.
• W4283456543 cites W2475334184 @default.
• W4283456543 cites W2512638651 @default.
• W4283456543 cites W2519510391 @default.
• W4283456543 cites W2607179358 @default.
• W4283456543 cites W2615714795 @default.
• W4283456543 cites W2619881304 @default.
• W4283456543 cites W2750733474 @default.
• W4283456543 cites W2752707491 @default.
• W4283456543 cites W2754041380 @default.
• W4283456543 cites W2765357488 @default.
• W4283456543 cites W2767391725 @default.
• W4283456543 cites W2771786039 @default.
• W4283456543 cites W2774621712 @default.
• W4283456543 cites W2793317048 @default.
• W4283456543 cites W2800876320 @default.
• W4283456543 cites W2808008353 @default.
• W4283456543 cites W2887432359 @default.
• W4283456543 cites W2887650349 @default.
• W4283456543 cites W2889526011 @default.
• W4283456543 cites W2894627590 @default.
• W4283456543 cites W2894993577 @default.
• W4283456543 cites W2899764361 @default.
• W4283456543 cites W2903911191 @default.
• W4283456543 cites W2906503176 @default.
• W4283456543 cites W2914569276 @default.
• W4283456543 cites W2916296804 @default.
• W4283456543 cites W2918092070 @default.
• W4283456543 cites W2922190016 @default.
• W4283456543 cites W2932399848 @default.
• W4283456543 cites W2934325311 @default.
• W4283456543 cites W2948519518 @default.
• W4283456543 cites W2948612418 @default.
• W4283456543 cites W2968073288 @default.
• W4283456543 cites W2989595227 @default.
• W4283456543 cites W3019508129 @default.
• W4283456543 cites W3045771605 @default.
• W4283456543 cites W3087691613 @default.
• W4283456543 cites W3092017935 @default.
• W4283456543 cites W3119881433 @default.
• W4283456543 cites W3173421961 @default.
• W4283456543 cites W3177365549 @default.
• W4283456543 cites W3195404919 @default.
• W4283456543 cites W3200446817 @default.
• W4283456543 cites W3212126026 @default.
• W4283456543 cites W4210615409 @default.
• W4283456543 cites W4250287496 @default.
• W4283456543 cites W4254445254 @default.
• W4283456543 doi "https://doi.org/10.1016/j.diabet.2022.101366" @default.
• W4283456543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35760374" @default.
• W4283456543 hasPublicationYear "2022" @default.
• W4283456543 type Work @default.
• W4283456543 citedByCount "4" @default.
• W4283456543 countsByYear W42834565432022 @default.
• W4283456543 countsByYear W42834565432023 @default.
• W4283456543 crossrefType "journal-article" @default.
• W4283456543 hasAuthorship W4283456543A5009232538 @default.
• W4283456543 hasAuthorship W4283456543A5019157994 @default.
• W4283456543 hasAuthorship W4283456543A5021900458 @default.
• W4283456543 hasAuthorship W4283456543A5054522724 @default.
• W4283456543 hasAuthorship W4283456543A5073994421 @default.
• W4283456543 hasConcept C126322002 @default.
• W4283456543 hasConcept C126894567 @default.
• W4283456543 hasConcept C134018914 @default.
• W4283456543 hasConcept C142724271 @default.
• W4283456543 hasConcept C159641895 @default.
• W4283456543 hasConcept C170493617 @default.
• W4283456543 hasConcept C185280430 @default.
• W4283456543 hasConcept C204787440 @default.
• W4283456543 hasConcept C27081682 @default.
• W4283456543 hasConcept C2777180221 @default.
• W4283456543 hasConcept C2778653478 @default.
• W4283456543 hasConcept C2778938600 @default.
• W4283456543 hasConcept C2780306776 @default.
• W4283456543 hasConcept C2781308992 @default.
• W4283456543 hasConcept C44249647 @default.

• next